US · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at -0.58 against a street estimate of -0.65 — a beat of 10.8%.
Analysts rate BioAge Labs, Inc a buy (7 buy, 2 hold, 0 sell out of 9) with an average price target of $35.62.
| Fund | Stake |
|---|---|
| BlackRock Inc | 6.21% |
| Cormorant Asset Management, LLC | 5.21% |
| Sofinnova Ventures | 5.00% |
| Jupiter Topco LLC | 4.67% |
| HHG PLC | 4.56% |
| Octagon Capital Advisors LP | 3.81% |
| RA Capital Management, LLC | 3.64% |
| MPM Oncology Impact Management LP | 3.63% |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for BioAge Labs, Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-19.